HUP0402041A2 - Csökkentett immunogenitású, módosított granulocita-kolonizációt stimuláló faktor (G-CSF) - Google Patents

Csökkentett immunogenitású, módosított granulocita-kolonizációt stimuláló faktor (G-CSF)

Info

Publication number
HUP0402041A2
HUP0402041A2 HU0402041A HUP0402041A HUP0402041A2 HU P0402041 A2 HUP0402041 A2 HU P0402041A2 HU 0402041 A HU0402041 A HU 0402041A HU P0402041 A HUP0402041 A HU P0402041A HU P0402041 A2 HUP0402041 A2 HU P0402041A2
Authority
HU
Hungary
Prior art keywords
csf
modified
polypeptides
reduced immunogenicity
humans
Prior art date
Application number
HU0402041A
Other languages
English (en)
Inventor
Francis J. Carr
Graham Carter
Tim Jones
Stephen Williams
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of HUP0402041A2 publication Critical patent/HUP0402041A2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/20—Protein or domain folding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S707/00—Data processing: database and file management or data structures
    • Y10S707/99941—Database schema or data structure
    • Y10S707/99943—Generating database or data structure, e.g. via user interface

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Evolutionary Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

A találmány tárgyát olyan polipeptidek képezik, amelyek - elsősorbanterápiás célból - speciálisan embereknek adagolhatók. A találmányszerinti polipeptidek módosított polipeptidek, mely módosításeredményeként a polipeptid - embereknek történő adagolása esetén -kevésbé hajlamos immunreakció kiváltására. Közelebbről, a találmánytárgyát humán granulocitakolonizációt stimuláló faktor (G-CSF)módosított változatai képezik, mely G-CSF-proteinváltozatok in vivoalkalmazáskor lényegében nem immunogének vagy kevésbé immunogének,mint a megfelelő, módosítás nélküli alakjuk. Szintén a találmánytárgyát képezik a nem módosított proteinből származó T-sejt-epitóppeptidek, valamint azok alkalmazása csökkent immunogenitású,módosított G-CSF-változatok előállítására. A találmány tárgyát képeziktovábbá a találmány szerinti módosított G-CSF-molekulákat kódoló DNS-ek, a találmány szerinti módosított G-CSF-molekulákat tartalmazógyógyászati készítmények, valamint eljárások a módosított G-CSF-molekulák előállítására. Ó
HU0402041A 2001-02-06 2002-02-05 Csökkentett immunogenitású, módosított granulocita-kolonizációt stimuláló faktor (G-CSF) HUP0402041A2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01102617 2001-02-06
EP01103954 2001-02-19
PCT/EP2002/001171 WO2002077034A2 (en) 2001-02-06 2002-02-05 Modified granulocyte colony stimulating factor (g-csf) with reduced immunogenicity

Publications (1)

Publication Number Publication Date
HUP0402041A2 true HUP0402041A2 (hu) 2005-01-28

Family

ID=26076460

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0402041A HUP0402041A2 (hu) 2001-02-06 2002-02-05 Csökkentett immunogenitású, módosított granulocita-kolonizációt stimuláló faktor (G-CSF)

Country Status (15)

Country Link
US (1) US7392141B2 (hu)
EP (1) EP1392731B1 (hu)
JP (1) JP2004527243A (hu)
KR (1) KR20030074785A (hu)
CN (1) CN1514844A (hu)
AT (1) ATE399794T1 (hu)
BR (1) BR0207020A (hu)
CA (1) CA2437287A1 (hu)
DE (1) DE60227367D1 (hu)
ES (1) ES2309168T3 (hu)
HU (1) HUP0402041A2 (hu)
MX (1) MXPA03007002A (hu)
PL (1) PL363501A1 (hu)
RU (1) RU2003125641A (hu)
WO (1) WO2002077034A2 (hu)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2498319A1 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
CA2691539C (en) * 2007-06-21 2014-08-26 Angelica Therapeutics, Inc. Modified toxins
WO2009110944A1 (en) * 2008-02-29 2009-09-11 Angelica Therapeutics, Inc. Modified toxins
RU2573909C2 (ru) 2010-03-04 2016-01-27 Пфенекс Инк. Способ получения растворимого рекомбинантного белка интерферона без денатурирования
AU2011235210B2 (en) 2010-04-01 2015-07-16 Pfenex Inc. Methods for G-CSF production in a Pseudomonas host cell
CA2902905A1 (en) 2013-03-15 2014-09-25 Claude Geoffrey Davis Modified toxins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO176799C (no) 1986-12-23 1995-05-31 Kyowa Hakko Kogyo Kk DNA som koder for et polypeptid, rekombinant plasmid som koder for og kan uttrykke et polypeptid og fremgangsmåte for fremstilling av dette polypeptid
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
DE69833755T2 (de) * 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
GB9712892D0 (en) 1997-06-20 1997-08-20 Eclagen Ltd Identification of mhc binding peptides
JP2002534959A (ja) 1998-12-08 2002-10-22 バイオベーション リミテッド 免疫原性タンパク質の改変方法

Also Published As

Publication number Publication date
JP2004527243A (ja) 2004-09-09
ES2309168T3 (es) 2008-12-16
WO2002077034A2 (en) 2002-10-03
EP1392731A2 (en) 2004-03-03
KR20030074785A (ko) 2003-09-19
CA2437287A1 (en) 2002-10-03
DE60227367D1 (de) 2008-08-14
MXPA03007002A (es) 2003-11-18
ATE399794T1 (de) 2008-07-15
US20040062749A1 (en) 2004-04-01
WO2002077034A3 (en) 2003-12-11
EP1392731B1 (en) 2008-07-02
US7392141B2 (en) 2008-06-24
RU2003125641A (ru) 2005-03-10
CN1514844A (zh) 2004-07-21
BR0207020A (pt) 2004-06-22
PL363501A1 (en) 2004-11-29

Similar Documents

Publication Publication Date Title
HUP0401534A2 (hu) Módosított humán IX. faktor
HUP0400700A2 (hu) Csökkentett immunogenitású, módosított humán agyi eredetű neutróf faktor (BDNF)
WO2004064759A3 (en) Use of tryptanthrin compounds for immune potentiation
YU72901A (sh) Preparati za primenu u terapiji i dijagnozi raka pluća
WO2005116051A3 (de) An mhc-moleküle bindende tumor-assoziierte peptide
CY1107973T1 (el) Σχετιζομενα με ογκους πεπτιδια, που συνδεονται ετεροκλητως με μορια κλασεως ιι αντιγονου ανθρωπινων λευκοκυτταρων
ATE314095T1 (de) Virusähnliche partikel zur induktion von autoantikörpern
IL186793A0 (en) Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease
HUP0402071A2 (hu) Csökkentett immunogenitású, módosított leptin
HUP0400703A2 (hu) Csökkentett immunogenitású módosított eritropoietin (EPO)
WO2000055345A3 (en) Therapy of cancer by insect cells containing recombinant baculovirus encoding genes
HUP0303534A2 (hu) Csökkent immunogenitású módosított interferon-béta
HUP0400698A2 (hu) Csökkentett immunogenitású módosított interleukin-1-receptor-antagonista (IL-1RA)
HUP0303430A2 (hu) Csökkentett immunogenitású, módosított protamin
UA91820C2 (ru) Терапевтическое применение вариантов хемокинов
EP1556513A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES MEDIATED BY THE HUMANE PAPILLOMA VIRUS
HUP0402041A2 (hu) Csökkentett immunogenitású, módosított granulocita-kolonizációt stimuláló faktor (G-CSF)
HUP0402334A2 (hu) Módosított humán növekedési hormon
HUP0303429A2 (hu) Csökkent immunogenitású módosított granulocita-makrofág kolóniastimuláló faktor (GM-CSF)
HUP0303309A2 (hu) Csökkentett immunogenitású módosított interferon-alfa
HUP0401121A2 (hu) Csökkentett immunogenitású, módosított trombopoietin (TPO)
HUP0303150A2 (hu) Csökkentett immunogenitású, módosított keratinocita növekedési faktor (KGF)
HUP0303310A2 (hu) Csökkentett immunogenitású módosított ciliáris neurotrofikus faktor (CNTF)
IL207012A (en) 28sgp medicinal product and 28sgp accent cancer treatment vaccine
HUP0302566A2 (hu) Készítmények és eljárások emlőrák gyógykezelésére és diagnosztizálására

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees